Compare Source Natural with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 83 Cr (Micro Cap)
28.00
35
0.00%
0.01
12.43%
3.63
Total Returns (Price + Dividend) 
Source Natural for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Source Natural Foods & Herbal Supplements Ltd is Rated Sell
Source Natural Foods & Herbal Supplements Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Source Natural Foods & Herbal Supplements Ltd Upgraded to Sell on Technical Improvements
Source Natural Foods & Herbal Supplements Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The change, effective from 16 April 2026, is driven primarily by improvements in technical indicators, while valuation and financial trends remain mixed, underscoring the complex investment landscape for this micro-cap pharmaceutical player.
Read full news article
Source Natural Foods & Herbal Supplements Ltd is Rated Strong Sell
Source Natural Foods & Herbal Supplements Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 05 Feb 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article Announcements 
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
27-Apr-2026 | Source : BSEFormat of the Annual Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Source Natural Foods and Herbal Supplements Ltd |
| 2 | CIN NO. | L24231KA1995PLC101742 |
| 3 | Report filed for FY | 2025-2026 |
| Details of the Current block (all figures in Rs crore): | ||
| 4 | 2 - year block period (Specify financial years)* | FY 2024-25 FY 2025-26 |
| 5 | Incremental borrowing done in FY (T)(a) | 0.00 |
| 6 | Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) | 0.00 |
| 7 | Actual borrowing done through debt securities in FY (T)(c) | 0.00 |
| 8 | Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) | 0 |
| 8 | Quantum of (d) which has been met from (c)(e)* | 0 |
| 9 | Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* | 0 |
| Details of penalty to be paid if any in respect to previous block (all figures in Rs crore): | |
| 2 - year Block period (Specify financial years) | FY 2024-25 FY 2025-26 |
| Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}# | 0.00 |
| Name of the Company Secretary :- | Yash Jain |
| Designation :- | Company Secretary |
| Name of the Chief Financial Officer :- | R Ramachandra |
| Designation : - | Chief Financial Officer |
Date: 27/04/2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
09-Apr-2026 | Source : BSECertificate under Regulation 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
31-Mar-2026 | Source : BSEClosure of Trading Window
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Sriveda Sattva Private Limited (74.37%)
Guttikonda Vara Lakshmi (2.96%)
18.7%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 19.76% vs 40.08% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is 17.14% vs 11.11% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 57.79% vs 47.63% in Sep 2024
Growth in half year ended Sep 2025 is 5.56% vs 173.91% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 71.00% vs 40.99% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -5.70% vs 60.56% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 64.54% vs 38.09% in Mar 2024
YoY Growth in year ended Mar 2025 is 66.67% vs -17.92% in Mar 2024






